• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Envoy Medical Inc.

    9/22/25 6:04:11 AM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email
    424B5 1 ea0258194-424b5_envoy.htm PROSPECTUS SUPPLEMENT

    As filed pursuant to Rule 424(b)(5)
    Registration No. 333-282474

     

    PROSPECTUS SUPPLEMENT
    (To Prospectus dated October 21, 2024
    and Prospectus Supplement dated January 17, 2025)

     

     

    Class A Common Stock

     

    This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated October 21, 2024 (the “Base Prospectus”) and the prospectus supplement dated January 17, 2025 (together with the Base Prospectus, the “ATM Prospectus”), relating to the offer and sale of shares of our Class A Common Stock (“Common Stock”) from time to time pursuant to the terms of At The Market Offering Agreement, dated as of January 17, 2025 (the “ATM Agreement”), with Roth Capital Partners, LLC (“Roth”) as sales agent. This Prospectus Supplement should be read in conjunction with the ATM Prospectus. This Prospectus Supplement is qualified by reference to theATM Prospectus, except to the extent that the information presented herein supersedes the information contained in theATM Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with the ATM Prospectus and the Base Prospectus and any future amendments or supplements thereto.

     

    In accordance with the terms of the ATM Agreement, we may offer and sell shares of our common stock from time to time through Roth pursuant to at-the-market transactions as defined in Rule 415 under the Securities Act of 1933, as amended, subject to the limitations described in theATM Prospectus (the “ATM Program”). As of the date of this Prospectus Supplement, we have sold an aggregate of 174,012 shares of our common stock pursuant to the ATM Agreement for aggregate gross proceeds of $266,060.

     

    The purpose of this Prospectus Supplement is to suspend theATM Program and to suspend the continuous offering by us under theATM Prospectus effective on September 22, 2025. We will not make any sales of our common stock through the ATM Program unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. However, for the avoidance of doubt, the ATM Agreement remains in full force and effect. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates is less than $75,000,000.

     

    Our Class A Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “COCH” and our Public Warrants are listed on Nasdaq under the symbol “COCHW.” On September 19, 2025, the last reported sale price of our Class A Common Stock was $1.31 per share.

     

    Investing in our securities involves a high degree of risk, including the risk of a substantial loss of investment. Before purchasing any shares of our common stock, you should read the discussion of the principal risks of investing in our securities, which are summarized in “Risk Factors” beginning on page S-4 of the ATM Prospectus and page 10 of the Base Prospectus, as well as in other documents incorporated by reference into the ATM Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus.Any representation to the contrary is a criminal offense.

     

    Roth Capital Partners

     

    The date of this prospectus suppplement is September 22, 2025

     

    Get the next $COCH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Taylor Glen A

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    9/8/25 5:17:48 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Taylor Glen A

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    7/8/25 10:37:33 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Potashnick Robert

    3 - Envoy Medical, Inc. (0001840877) (Issuer)

    7/3/25 2:48:15 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical to Participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) Conference on October 11th-14th

    White Bear Lake, Minnesota--(Newsfile Corp. - October 1, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that management will participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference taking place on October 11th-14th, 2025 in Indianapolis, IN, at the Indiana Convention Center and JW Marriott Indianapolis.At the conference, Envoy Medical will meet individually with interested implanting surgeons to review recent developments related to both of its products and provide a company update. Registered attendees can request a meeting by

    10/1/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    White Bear Lake, Minnesota--(Newsfile Corp. - September 25, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock. In addition, in a concurrent private placement, Envoy Medical issued and sold unregistered warrants to purchase up to 5,725,206 shares of Class A common stock. The unregistered warrants have an exercise price of $1.31 per share of Class A common sto

    9/25/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Advances Commercialization Planning for Breakthrough Hearing Device as FDA Clinical Trial Remains On Track

    The Company Begins Strategic Preparations To Support Anticipated Demand And Optimization Of The Acclaim® Fully Implanted Cochlear Implant OpportunitySix-month follow-up visits are now underway and will continue over the next two monthsWhite Bear Lake, Minnesota--(Newsfile Corp. - September 24, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it is scaling its commercialization planning for the company's breakthrough investigational Acclaim® fully implanted hearing device, as its pivotal clinical trial continues to build momentum. The Company's proactive approach reflects

    9/24/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/13/25 4:10:30 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/10/25 4:11:23 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    5/27/25 6:34:31 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    9/23/25 9:56:40 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by Envoy Medical Inc.

    424B5 - Envoy Medical, Inc. (0001840877) (Filer)

    9/23/25 9:53:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by Envoy Medical Inc.

    424B5 - Envoy Medical, Inc. (0001840877) (Filer)

    9/22/25 6:04:11 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

    Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

    6/24/24 7:29:10 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Financials

    Live finance-specific insights

    View All

    Envoy Medical Reports on Second Quarter 2025 Results

    White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A

    7/31/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports on First Quarter 2025 Results

    Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

    5/1/25 4:30:00 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

    3/31/25 9:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

    WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

    6/11/24 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical to Host Fireside Chat Event December 7

    Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

    12/4/23 8:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/13/24 4:40:10 PM ET
    $COCH
    Industrial Specialties
    Health Care